Merit Medical Systems Files 8-K
Ticker: MMSI · Form: 8-K · Filed: Oct 17, 2025 · CIK: 856982
| Field | Detail |
|---|---|
| Company | Merit Medical Systems Inc (MMSI) |
| Form Type | 8-K |
| Filed Date | Oct 17, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $22 m, $19 million, $3 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, regulation-fd
TL;DR
MERIT filed an 8-K, standard procedure, no major news yet.
AI Summary
On October 15, 2025, Merit Medical Systems, Inc. filed an 8-K report to disclose information under Regulation FD and to file financial statements and exhibits. The filing does not contain specific financial figures or material events beyond the procedural disclosure.
Why It Matters
This 8-K filing serves as a formal notification to the SEC and the public about the company's reporting status and the submission of required documents.
Risk Assessment
Risk Level: low — The filing is a routine procedural disclosure and does not contain any new material information that would impact the company's risk profile.
Key Players & Entities
- MERIT MEDICAL SYSTEMS INC (company) — Registrant
- 0000856982-25-000050 (document_id) — Accession Number
- October 15, 2025 (date) — Date of Report
- Utah (location) — State of Incorporation
- 870447695 (tax_id) — EIN
- 1600 West Merit Parkway (address) — Principal Executive Offices
- South Jordan (location) — City
- 84095 (zip_code) — Zip Code
FAQ
What is the primary purpose of this 8-K filing for Merit Medical Systems, Inc.?
The primary purpose is to report information under Regulation FD and to file financial statements and exhibits as of October 15, 2025.
What is the accession number for this filing?
The accession number is 0000856982-25-000050.
When was the report filed?
The report was filed as of October 17, 2025, with the earliest event reported on October 15, 2025.
In which state is Merit Medical Systems, Inc. incorporated?
Merit Medical Systems, Inc. is incorporated in Utah.
What is the company's principal executive office address?
The principal executive office is located at 1600 West Merit Parkway, South Jordan, Utah 84095.
Filing Stats: 1,180 words · 5 min read · ~4 pages · Grade level 14.3 · Accepted 2025-10-17 16:03:40
Key Financial Figures
- $22 m — nc. for total purchase consideration of $22 million, consisting of a $19 million cash
- $19 million — eration of $22 million, consisting of a $19 million cash payment at closing and potential c
- $3 million — potential contingent payments of up to $3 million payable upon meeting certain milestones
Filing Documents
- mmsi-20251015x8k.htm (8-K) — 51KB
- mmsi-20251015xex99d1.htm (EX-99.1) — 32KB
- mmsi-20251015x8k001.jpg (GRAPHIC) — 11KB
- mmsi-20251015xex99d1001.jpg (GRAPHIC) — 21KB
- 0000856982-25-000050.txt ( ) — 262KB
- mmsi-20251015.xsd (EX-101.SCH) — 3KB
- mmsi-20251015_lab.xml (EX-101.LAB) — 15KB
- mmsi-20251015_pre.xml (EX-101.PRE) — 9KB
- mmsi-20251015x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On October 15, 2025, Merit Medical Systems, Inc. ("Merit") issued a press release (the "Acquisition Press Release") announcing it has signed a definitive asset purchase agreement with Pentax of America, Inc., a subsidiary of PENTAX Medical, Inc., to acquire the C2 CryoBalloon device and related technology. The closing of the proposed transaction is expected to occur during the fourth quarter of 2025, subject to the satisfaction or waiver (in accordance with the provisions of the asset purchase agreement) of certain customary closing conditions. Merit proposes to acquire the C2 CryoBalloon assets from Pentax of America, Inc. for total purchase consideration of $22 million, consisting of a $19 million cash payment at closing and potential contingent payments of up to $3 million payable upon meeting certain milestones. A copy of the Acquisition Press Release is included as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Merit is making reference to non-GAAP information in the Acquisition Press Release. A quantitative reconciliation of such non-GAAP financial information to comparable GAAP financial information is not available without unreasonable effort. The information contained in this Item 7.01 of this Current Report and in the attached Exhibit 99.1 is furnished pursuant to General Instruction B.2. of Form 8-K and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by Merit under the Securities Act of 1933, as amended (the "Securities Act"), or the Securities Exchange Act of 1934, as amended (the "Exchange Act"). CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS The information included in this Current Report contains forward-looking statements about Merit that involve substantial risks and uncertainties. Merit intends such st
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits EXHIBIT NUMBER DESCRIPTION 99.1 Press Release, dated October 15 , 2025 , entitled " Merit Medical Signs Asset Purchase Agreement with PENTAX Medical to acquire C2 CryoBalloon Technology . " 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MERIT MEDICAL SYSTEMS, INC. Date: October 17, 2025 By: /s/ Brian G. Lloyd Brian G. Lloyd Chief Legal Officer and Corporate Secretary 4